ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

HCM Hutchmed (china) Limited

219.00
-1.00 (-0.45%)
24 Jan 2025 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Hutchmed (china) Limited HCM London Ordinary Share
  Price Change Price Change % Share Price Last Trade
-1.00 -0.45% 219.00 16:35:14
Open Price Low Price High Price Close Price Previous Close
217.00 217.00 220.00 219.00 220.00
more quote information »
Industry Sector
PHARMACEUTICALS & BIOTECHNOLOGY

Hutchmed (china) HCM Dividends History

No dividends issued between 26 Jan 2015 and 26 Jan 2025

Top Dividend Posts

Top Posts
Posted at 14/1/2025 08:38 by waldron
Press Release


HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC



- Indication expands to include treatment-naïve patients -



- The 2021 conditional approval in previously treated patients converted to full approval -



Hong Kong, Shanghai & Florham Park, NJ - Tuesday, January 14, 2025: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) today announces that the supplemental New Drug Application for ORPATHYS® (savolitinib) has been granted approval by the China National Medical Products Administration ("NMPA") for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer ("NSCLC") with MET exon 14 skipping alteration. The NMPA has also converted the prior conditional approval of ORPATHYS® in the previously treated patient population to full approval. The new label indication for ORPATHYS® will now include both treatment-naïve and previously treated patients in China.
Posted at 01/1/2025 11:34 by 1jat
And today a deal to dispose of SHPL has been announced for $608m.

Call on Tuesday, EGM required due to size of the transaction.

What will they do with this extra cash…..no fund raise was expected to deliver the pipeline….so it will likely mean M&A, or return to Shareholders (BB or divi?)

Shorts likely to run for the hills would be my guess and an opening jump in the share price on 2 Jan.
Posted at 09/12/2024 18:05 by fillipe
HCM deserves more than the only +4p of the day, even after also recovering from a poor opening.
Folks will surely catch on as the days go by, if they have the insight.

f
Posted at 29/11/2024 09:03 by shaker45
Just more sellers than reasons to buy. Markets looking toppy, more negative economic news from China. Probably nothing hcm specific.
Posted at 22/11/2024 04:58 by lauders
Good news from HCM today: HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan

They also received a milestone payment from Takeda as a consequence.
Posted at 12/11/2024 07:28 by 1jat
AZ has reported Orpathys sales of $36m for the 9m to end September.
This is consistent with the H1 run rate and FY sales should be close to $50m.

The Savannah read out was the first item in the pipeline update. HCM has stated in the November corporate presentation that they expect AZ to submit the US NDA in 2024. They also mention accelerated approval, so we may see an approval late in 2025, both events are likely to trigger milestone payments followed by sales milestones and royalties in 2026.
Posted at 17/10/2024 13:32 by 1jat
Arguably both cash flow + and - lead to M&A - one as the major party and one as the minor party.

There are a lot of biotechs in China and there are significant efficiencies possible across pipeline assets, sales and general administration. New money is hard to raise but mergers are likely to be encouraged by the mainland to build some national champions (globally China cos are not in the big pharma league - that should change).

If CKHH is willing to back HCM issuing new equity or taking on some debt, then it should be possible for HCM to take the lead on some M&A deals and grow inorganically - that is how big Pharma got to be big rather than organic growth.

Pre-commercial deals - will come with more uncertainty but the target will bring some cash and R&D capabilities. The main economies will come from pushing more volume through the factory and sales channels when the acquired products are approved.

Commercial stage deals - Should generate value for both shareholders due to the large synergies…..balance sheet management will drive the cash/equity offer and debt levels taken on.

I dont think HCM has the management to do a significant merger at the moment, so if they are to be on the front foot I would expect a new CEO and a strategy director to be appointed first.
Posted at 30/8/2024 17:25 by 1jat
I dont expect anything to happen quickly - but I hope this triggers a thought that it might be a good idea to separate the roles of CEO and CSO……and they need to appoint some new management to both roles.

I would also like CKHH to review its strategy for HCM. I suspect HCM shareholders would be materially better off if it was part of a larger organisation where the commercial teams can be rationalised / leveraged along with the pipeline better prioritised. That could mean bringing in new management and then acquiring other businesses, or selling to a rival.
Posted at 30/7/2024 09:23 by 1jat
As with all things M&A for HCM, it will come down to CKHH.
China wants its raise its markets by encouraging firms to be more commercially oriented and provide value to owners…..
Beigene is probably the most successful of its younger biotechs but is still small compared to big pharma.
I expect there will be a wave of consolidation M&A within the chinese biotechs, and HCM will participate…
The economics would appear compelling…230;.if you merged HCM with any of Junshi, Innovent, Beigene there would be significant operational overlaps across the whole develop, register, manufacture and sales processes as well as competing products that can be rationalised. In addition the companies have raised funds some of which is looking like excess capital which can be paid out in merger / dividends.

The big news tomorrow will be Takeda’s sales in the US……they should have grown sales from the $50m in Q1 but by how much? Closer to $80m and it will look like the patient population is growing and could be much higher than the $200m pa currently penciled in by analysts.
The rest of the year will be dominated by:
1 news of regulatory approvals with three reviews ongoing in China and one in Japan.
2 early sales in Europe by Takeda
3 AZ submitting Savolitinib for approval in the US.
4 Possible partner for Sovlep.
Posted at 12/7/2024 06:35 by 1jat
It seems that Goldman is in at CKHH and its reviews are proving a little leaky,
Two stories in two days about the European Three mobile telecoms businesses and a second about CK Infrastructure.

When they get to HCM it will be no surprise if they suggest M&A with other China biotech (I would not expect HCM to be the buyer as that would not generate immediate gains for CKHH). They should be having these discussions about reaising SH value from time to time.
IMO CKHH has incubated HCM and may decide it does not have the resources/appetite to take it much further or the ability as a Board to oversee this specialist investment and therefore seeks to dilute its ownership.
If they can get a proposal above hk$50 they will be obliged to seriously consider it. CK deals have often involved a mix of cash and listed shares followed by sell downs (eg recent mobile mast deal in Europe).
No certainty of a deal emerging, but I feel there is change coming at CKHH and HCM may not be untouched by it.

Your Recent History